Provided by Tiger Fintech (Singapore) Pte. Ltd.

Agree

76.01
-1.0100-1.31%
Post-market: 76.010.00000.00%17:28 EDT
Volume:1.58M
Turnover:120.28M
Market Cap:8.14B
PE:42.70
High:77.16
Open:77.03
Low:75.83
Close:77.02
Loading ...

BioNTech to Report Fourth Quarter and Full Year 2024 Financial Results and Corporate Update on March 10, 2025

GlobeNewswire
·
24 Feb

Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos

Dow Jones
·
24 Feb

OPTIMUM AND MSG NETWORKS AGREE ON CARRIAGE DEAL

PR Newswire
·
23 Feb

Akari Therapeutics Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

GlobeNewswire
·
19 Feb

Sonnet BioTherapeutics Announces That Its Proprietary Antibody Drug Conjugate (ADC) Platform is Available for Drug Discovery Partnerships with Potential for Producing Multiple Pipeline Drug Candidates

GlobeNewswire
·
19 Feb

Lantern Pharma Announces PCT Patent Application Publication for Innovative, High Performing, Machine Learning Model for Predicting Blood Brain Barrier Permeability of Drug-Candidates

Business Wire
·
19 Feb

Creators Insist Coupon Browser Extensions Are Stealing Their Money. Will the Courts Agree? -- WSJ

Dow Jones
·
19 Feb

GoviEx Uranium and Niger Agree on Roadmap for Madaouela Project Dispute

TIPRANKS
·
18 Feb

Audinate Bulls Agree That Headwinds Are Cyclical -- Market Talk

Dow Jones
·
18 Feb

Innate Pharma Announces U.S. FDA Granted Breakthrough Therapy Designation to Lacutamab for Relapsed or Refractory Sézary Syndrome

Business Wire
·
17 Feb

Agree Realty Corporation (ADC): Among the Best Stocks That Pay Monthly Dividends in 2025

Insider Monkey
·
14 Feb

F5 Inc. (FFIV) Unveils ADC 3.0 to Revolutionize AI-Powered Application Delivery and Security

Insider Monkey
·
14 Feb

Neutral Outlook on Agree Realty Amid Adjusted Projections and Unchanged Price Target

TIPRANKS
·
13 Feb

RBC Trims Price Target on Agree Realty to $78 From $79, Keeps Outperform Rating

MT Newswires Live
·
13 Feb

Israel and Hamas Agree to Resolve Cease-Fire Dispute -- WSJ

Dow Jones
·
13 Feb

IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

PR Newswire
·
13 Feb